Development of novel therapeutic approaches and targets for Parkinson's disease.
- Toth G, Gardai SJ, Zago W, Bertoncini CW, Cremades N, Roy SL, Tambe MA, Rochet JC, Galvagnion C, Skibinski G, Finkbeiner S, Bova M, Regnstrom K, Chiou SS, Johnston J, Callaway K, Anderson JP, Jobling MF, Buell AK, Yednock TA, Knowles TP, Vendruscolo M, Christodoulou J, Dobson CM, Schenk D, McConlogue L. (2014) ÒTargeting the Monomeric State of Alpha-Synuclein as a Therapeutic Strategy for ParkinsonÕs DiseaseÓ PLoS One. Volume 9(2): e87133. PMCID: PMC3925190
- Pickhardt M, Neumann T, Schwizer D, Callaway K, Vendruscolo M, Schenk D, George-Hyslop PS, Mandelkow EM, Dobson CM, McConlogue L, Mandelkow E, Toth G. (2015) Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies. Curr Alzheimer Res. Volume 12:814-28. PMID: 26510979.
- Gardai SJ, et al. (2013) Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One. Volume 8(8):e71634. PMCID: PMC3751933
- Masliah E, Rockenstein E, Mante M, Crews L, Spencer B, Adame A, Patrick C, Trejo M, Ubhi K, Rohn TT, Mueller-Steiner S, Seubert P, Barbour R, McConlogue L, Buttini M, Games D, Schenk D. (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One. Volume 6 issue 4:e19338. PMCID: PMC3084838.
- Inglis KJ, et al (2009) Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J Biol Chem. 284:2598-602 doi: 10.1074/jbc.C800206200. PMCID: PMC2631975
Development of animal models for Alzheimer's disease and application to discovery.
- Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L (2000) High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20(11):4050-8. PMID: 11106573
- Johnson-Wood, K., Lee, M., Motter, R., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M., Tan, H., Games, D., Lieberburg, I., Schenk, D., Seubert. P., McConlogue, L. (1997) Amyloid precursor protein processing and A?42 deposition in a transgenic mouse model of Alzheimer disease, Proc. Natl. Acad. Sci., USA, 94:1550-1555
- Games, D., Adams, D., Alessandrini, T., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., Guido, T., Hagopian, S., Johnson-Wood, K., Khan, K., Lee, M., Leibowitz, P., Lieberburg, I., Little, S., Masliah, E., McConlogue, L., Montoya-Zavala, M., Mucke, L., Paganini, P., Penniman, E., Power, M., Schenk, D., Seubert, P., Snyder, B., Soriano, F., Tan, H., Vitale, J., Wadsworth, JS., Wolozin, B., Zhao, J. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373:523-527.
- Lisa C. McConlogue and Jun Zhao (1998) "Transgenic Rodents Harboring APP Allele Having Swedish Mutation". US patents #5,850,003, US 5,612,486
Identification and characterization of BACE, a novel and critical therapeutic target for Alzheimer's disease (AD).
- Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, Freedman SB, Frigon NL, Games D, Hu K, Johnson-Wood K, Kappenman KE, Kawabe TT, Kola I, Kuehn R, Lee M, Liu W, Motter R, Nichols NF, Power M, Robertson DW, Schenk D, Schoor M, Shopp GM, Shuck ME, Sinha S, Svensson KA, Tatsuno G, Tintrup H, Wijsman J, Wright S, McConlogue L (2001). BACE knockout mice are healthy despite lacking the primary b-secretase activity in brain: implications for AlzheimerÕs disease therapeutics. Human Molecular genetics 10:1-8.
- Lisa C. McConlogue and Mark E Gurney Transgenic Knockouts of BACE-1: Animal Model for use in diagnosing and Treating Nervous System Disorders.Ó (2007) Patent # US 7309811
- Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, Doan M, Dovey HF, Frigon N, Hong J,Jacobson-Croak K, Jewett N, Keim P, Knops J, Lieberburg I, Power M, Tan H, Tatsuno G, Tung J, Schenk D, Seubert P, Suomensaari SM, Wang S, Walker D, Zhao J, McConlogue L, John V (1999) Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402:537-40
- J. P Anderson, G. Basi, Minh, T. Doane, N.Frigon, V. John, M. Power, S. Sinha, G. Tatsuno, J. Tung, S. Wang, McConlogue, Lisa. (2006). Òβ–Secretase Enzyme Compositions And MethodsÓ. Patents # US6627739; US 7,067,271; US 7115410; US 7109017; US 7,252,963; US 7262043; US 7,276,349, US 7427478 and US 7456007.
Characterization of processing of the Amyloid Precursor Protein (APP) to A? peptide- a key driver of Alzheimer's disease.
- Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A., Seubert, P., Vigo-Pellfrey, C., Lieberburg, I. and Selkoe, D. (1992) Mutation of the β-amyloid precursor protein in familial Alzhemer's disease increases §-protein production. Nature 360:672-674.
- Sinha S, Anderson J, John V, McConlogue L, Basi G, Thorsett E, Schenk D. (2000) Recent advances in the understanding of the processing of APP to beta amyloid peptide. Ann N Y Acad Sci. 2000;920:206-8.
Complete publication list: